E-resources
PDF-
van Erp, Francine C., MD; Knol, Edward F., PhD; Pontoppidan, Bo, PhD; Meijer, Yolanda, MD; van der Ent, Cornelis K., MD, PhD; Knulst, André C., MD, PhD
Journal of allergy and clinical immunology, 01/2017, Volume: 139, Issue: 1Journal Article
The occurrence of nonreleasers (10% in our study) is a major drawback because in those subjects the BAT cannot be interpreted.\n1 (0.1-0.1) 0.1 (0.1-7.72) 1.4 (0.1-35.38) .005 .18 sIgE Ara h 2 (kUA/L) 81 0.1 (0.1-0.39) 4.8 (1.06-20.18) 10.18 (3.54-38.97) <.001 .19 sIgE Ara h 3double dagger (kUA/L) 77 0.1 (0.1-0.14) 0.1 (0.1-0.4) 0.26 (0.14-4.87) .02 .04 sIgE Ara h 3 imputed (kUA/L) 81 0.1 (0.1-0.14) 0.1 (0.1-0.4) 0.23 (0.1-4.87) .02 .09 sIgE Ara h 6double dagger (kUA/L) 77 0.1 (0.1-0.21) 2.47 (1.12-23.57) 16.11 (5.29-24.09) <.001 .06 sIgE Ara h 6 imputed (kUA/L) 81 0.1 (0.1-0.21) 2.47 (1.12-18.06) 12.63 (5.29-24.09) <.001 .04 sIgE Ara h 8 (kUA/L) 81 0.47 (0.1-4.19) 2.1 (0.23-7.14) 0.33 (0.1-7.05) .28 .34 sIgE Ara h 9double dagger (kUA/L) 77 0.1 (0.1-0.1) 0.1 (0.1-0.1) 0.1 (0.1-0.13) .42 .03 sIgE Ara h 9 imputed (kUA/L) 81 0.1 (0.1-0.1) 0.1 (0.1-0.1) 0.1 (0.1-0.17) .27 .05 BAT§ n      Ara h 2 Maximal CD63% 73 2.3 (1-4.6) 50.05 (21.9-64.9) 41.1 (17.85-63.65) <.001 .75 Maximal CD63%/aIgE 73 7.79 (4-22) 102.48 (62.64-139.97) 109.19 (66.47-167.98) <.001 .73 Mean CD63% 10-100 μg 73 1.1 (0.6-1.95) 31.73 (14.43-52.08) 32.2 (10.68-47.33) <.001 .89 Mean CD63%/aIgE 73 4 (1.73-10.39) 79.82 (33.45-105.77) 78.63 (43.73-110.89) <.001 .67 CD-sens 73 0.01 (0.01-0.01) 23.31 (14.51-60.21) 19.81 (2.52-31.02) <.001 .19 AUC 73 5.42 (2.3-7.77) 100.3 (36.42-160.8) 84.69 (32.89-123.8) <.001 .47 Ara h 6 Maximal CD63% 73 1.9 (1.2-3.5) 48.65 (25.55-65.6) 54 (41.7-58.55) <.001 .67 Maximal CD63%/aIgE 73 6.49 (3.23-21.84) 104.07 (60.18-130.82) 120.56 (90.07-199.07) <.001 .17 Mean CD63% 10-100 μg 73 1.15 (0.5-2.25) 36.15 (11.6-58.95) 37.45 (30.93-44.1) <.001 .83 Mean CD63%/aIgE 73 4.18 (1.45-17.24) 85.12 (27.62-109.82) 93.01 (64.8-143.02) <.001 .32 CD-sens|| 72 0.01 (0.01-0.01) 16.82 (1.98-21.9) 11.71 (3.89-26.15) <.001 .47 AUC 73 4.52 (2.31-7.07) 91 (30.17-150.95) 97.66 (76.07-107.25) <.001 .81 Table E2 Diagnostic tests under study in tolerant, mild-moderate, or severe peanut allergic children P values in boldface indicate a significant difference between the outcome groups (allergic vs tolerant or mild/moderate vs severe).aIgE, Anti-IgE; AUC, area under the dose response curve; sIgE, specific IgE.
